Interphase detection of t(4;14)(p16.3;q32.3) by in situ hybridization and FGFR3 overexpression in plasma cell malignancies

Cancer Genetics and Cytogenetics

Volumn 117, Issue 2, 2000, Pages 89-96

  Nakazawa, Naozo ^a   Nishida, Kazuhiro ^a   Tamura, Akiko ^a   Kobayashi, Miyako ^a   Iwai, Toshiki ^a   Horiike, Shigeo ^a   Nishigaki, Hikari ^b   Otsuki, Takemi ^c   Tomiyama, Yoshiaki ^d   Fujii, Hiroshi ^e   Kashima, Kei ^a   Taniwaki, Masafumi ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b Otsu Municipal Hospital   (Japan)

^c KAWASAKI MEDICAL SCHOOL   (Japan)

^d OSAKA UNIVERSITY   (Japan)

^e KYOTO FIRST RED CROSS HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CHROMOSOME 4P; CHROMOSOME ANALYSIS; CHROMOSOME BANDING PATTERN; CHROMOSOME TRANSLOCATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; FEMALE; GENE FREQUENCY; GENE FUSION; GENE LOCUS; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN SITU HYBRIDIZATION; INTERPHASE; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; CHROMOSOME BANDING; CHROMOSOMES, HUMAN, PAIR 14; CHROMOSOMES, HUMAN, PAIR 4; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IN SITU HYBRIDIZATION, FLUORESCENCE; INTERPHASE; KARYOTYPING; LEUKEMIA, PLASMACYTIC; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PLASMACYTOMA; PROTEIN-TYROSINE KINASES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; RECEPTORS, FIBROBLAST GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSLOCATION, GENETIC;

EID: 0033993429     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-4608(99)00155-7     Document Type: Article

References (39)

1. Hallek M., Bergsagel P.L., Anderson K.C. Multiple myeloma. increased evidence for a multistep transformation process Blood. 91:1998;3-21.
2. Bergsagel P.L., Chesi M., Nardini E., Brents L.A., Kirby S.L., Kuehl W.M. Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. Proc Natl Acad Sci USA. 93:1996;13931-13936.
3. Chesi M., Nardini E., Brents L.A., Shröck E., Ried T., Kuehl W.M., Bergsagel P.L. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nature Genet. 16:1997;260-264.
4. Iida S., Rao P.H., Butler M., Corradini P., Boccadoro M., Klein B., Chaganti R.S., Dalla-Favera R. Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma. Nature Genet. 17:1997;226-230.
5. Chesi M., Bergsagel P.L., Shonukan O.O., Martellli M.L., Brents L.A., Chen T., Schröck E., Reid T., Kuehl M. Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. Blood. 91:1998;4457-4463.
6. Nishida K., Tamura A., Nakazawa N., Ueda Y., Abe T., Matsuda F., Kashima K., Taniwaki M. The immunoglobulin heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization. Blood. 90:1997;526-534.
7. Dewald G.W., Kyle R.A., Hicks G.A., Greipp P.R. The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis. Blood. 66:1985;380-390.
8. Gould J., Alexanian R., Goodace A., Pathak S., Hecht B., Barlogie B. Plasma cell karyotype in multiple myeloma. Blood. 71:1988;453-456.
9. Taniwaki M., Nishida K., Takashima T., Nakagawa H., Fujii H., Tamaki T., Shimazaki C., Horiike S., Misawa S., Abe T., Kashima K. Nonrandom chromosomal rearrangements of 14q32.3 and 19p13.3 and preferential deletion of 1p in 21 patients with multiple myeloma and plasma cell leukemia. Blood. 84:1994;2283-2290.
10. Sawyer J.R., Waldron J.A., Jagannath S., Barlogie B. Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet. 82:1995;41-49.
11. Lai J.L., Zandecki M., Mary J.Y., Bernardi F., Izydorczyk V., Flactif M., Morel P., Joouet J.P., Bauters F., Facon T. Improved cytogenetics in multiple myeloma. a study of 151 patients including 117 patients at diagnosis Blood. 85:1995;2490-2497.
12. Calazanz M.L., Cigudosa J.C., Odero M.D., Ferreira C., Andanaz M.T., Fraile A., Carrasco J.L., Sole F., Cuesta B., Gullon A. Cytogenetic analysis of 280 patients with multiple myeloma and related disorders. primary breakpoints and clinical correlations Genes Chromosom Cancer. 18:1997;84-93.
13. Durie B.G.M., Grogan T.M., Spier C., Vela E., Baum V., Rodriguez M.A., Frutiger Y. Myelomonocytic myeloma cell line (LB 84-1). Blood. 73:1989;770-776.
14. Rao P.H., Cigudosa J.C., Ning Y., Calasanz M.J., Iida S., Tagawa S., Michaeli J., Klein B., Dalla-Favera R., Jhanwar S.C., Ried T., Chaganti R.S.K. Multicolor spectral karyotyping identifies new recurring breakpoints and translocations in multiple myeloma. Blood. 92:1998;1743-1748.
15. Sawyer J.R., Lukacs J.L., Munshi N., Desikan K.R., Singhal S., Mehta J., Siegel D., Shaughnessy J., Barlogie B. Identification of new nonrandom translocations in multiple myeloma with multicolor spectral karyotyping. Blood. 92:1998;4269-4278.
16. Saccone S., De Sario A., Della Valle G., Bernardi G. The highest gene concentrations in the human genome are in telomeric bands of metaphase chromosomes. Proc Natl Acad Sci USA. 89:1992;4913-4917.
17. Richelda R., Ronchetti D., Baldini L., Cro L., Viggiano L., Marzella R., Rocchi R., Otsuki T., Lombardi L., Maiolo A.T., Neri A. A novel chromosomal translocation t(4;14)(p16.3;q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene. Blood. 90:1997;4062-4070.
18. Kosmo M.A., Gale R.P. Plasma cell leukemia. Semin Hematol. 24:1987;202-208.
19. Otsuki T., Nakazawa N., Taniwaki M., Yamada O., Sakaguchi H., Wada H., Yawata Y., Ueki A. Establishment of a new human myeloma cell line, KMS-18, having t(4;14)(p16.3;q32.3) derived from a case phenotypically transformed from IgA-λ to BJP-λ, and associated with hyperammonemia. Int J Oncol. 12:1998;545-552.
20. Katagiri S., Yonezawa T., Kuyama J., Kanayama Y., Nishida K., Abe T., Tamaki T., Ohnishi M., Tarui S. Two distinct human myeloma cell lines originating from one patient with myeloma. Int J Cancer. 36:1985;241-246.
21. ISCN (1995): An Internal System for Human Cytogenetic Nomenclature. Report of the standing committee on human cytogenetic nomenclature. Mitelman F, ed. Karger, Basel.
22. Taniwaki M., Nishida K., Ueda Y., Misawa S., Nagai M., Tagawa S., Yamagami T., Sugiyam H., Abe M., Fukuhara S., Kashima K. Interphase and metaphase detection of the breakpoint of 14q32 translocations in B-cell malignancies by double-color fluorescence in situ hybridization. Blood. 85:1995;3223-3228.
23. Perez-Castro A.V., Wilson J., Altherr M.R. Genomic organization of the human fibroblast growth factor receptor 3 (FGFR3) gene and comparative sequence analysis with the mouse Fgfr3 gene. Genomics. 41:1997;10-16.
24. Taniwaki M., Silverman G.A., Nishida K., Horiike S., Misawa S., Shimazaki C., Miura I., Nagai M., Abe M., Fukuhara S., Kashima K. Translocations and amplification of the BCL2 gene are detected in interphase nuclei of non-Hodgkin's lymphoma by in situ hybridization with yeast artificial chromosome clones. Blood. 86:1995;1481-1486.
25. Chomcynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 162:1987;156-159.
26. Ponte P., Ng S.Y., Engel J., Gunning P., Kedes L. Evolutionary conservation in the untranslated regions of actin mRNA. DNA sequence of a human beta-actin cDNA Nucleic Acids Res. 12:1984;1687-1696.
27. Kyle R.A. Diagnostic criteria of multiple myeloma. Hematol Oncol Clin North Am. 6:1992;347-358.
28. Durie B., Salmon S. A clinical staging system for multiple myeloma. Cancer. 36:1975;842-854.
29. Oken M.M., Creech R.H., Tormey D.C., Horton J., Davis T.E., McFadden E.T., Carbone P.P. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 5:1982;649-655.
30. Avet-Loiseau H., Li J.Y., Facon T., Brigaudeau C., Morineau N., Maloisel F., Rapp M.J., Talmant P., Trimoreau F., Jaccard A., Harousseah J.L., Bataille R. High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies. Cancer Res. 58:1998;5640-5645.
31. Avet-Loiseau H., Brigaudeau C., Morineau N., Talmant P., Lai J.L., Daviet A., Li J.Y., Praloran V., Rapp M.J., Harousseau J.L., Facon T., Bataille R. High incidence of cryptic translocations involving the Ig heavy chain gene in multiple myeloma, as shown by fluorescence in situ hybridization. Genes Chromosom Cancer. 24:1999;9-15.
32. Chesi M., Nardini E., Lim R.S.C., Smith K.D., Kuehl W.M., Bergsagel P.L. The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood. 92:1998;3025-3034.
33. Taub R., Kelly K., Battery J., Latt S., Lenoir G.M., Tantravahi U., Tu Z., Leder P. A novel alteration in the structure of an activated c-myc gene in a variant t(2;8) Burkitt lymphoma. Cell. 37:1984;511-520.
34. Adachi M., Cossmaan J., Longo D., Croce C.M., Tsujimoto Y. Variant translocation of the bcl-2 gene to immunoglobulin lambda light chain gene in chronic lymphocytic leukemia. Proc Natl Acad Sci USA. 86:1989;2771-2774.
35. Komatsu H., Iida S., Yamamoto K., Mikuni C., Nitta M., Takahashi T., Ueda R., Seto M. A variant chromosome translocation at 11q13 identifying PRAD1/cyclin D1 as the BCL-1 gene. Blood. 84:1994;1226-1231.
36. Smith L., Barlogie B., Alexanian R. Biclonal and hypodiploid multiple myeloma. Am J Med. 80:1986;841-843.
37. Epstein J., Xiao H., He X.Y. Marker of multiple hematopoietic-cell lineages in multiple myeloma. New Engl J Med. 322:1990;664-668.
38. Billadeau D., Ahmann G., Greipp P., van Ness B. The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell. J Exp Med. 178:1993;1023-1031.
39. Muenke M., Schell U. Fibroblast-growth-factor receptor mutations in human skeletal disorders. Trends Genet. 11:1995;308-313.